FDA approval of XHANCE™ (fluticasone propionate)

Optinose Announces FDA approval of XHANCE™ (fluticasone propionate) nasal spray for the treatment of nasal polyps

YARDLEY, PA, September 18, 2017 — Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application (NDA) for XHANCE (previously referred to by the development name OPN-375) for the treatment of nasal polyps in patients 18 years of age and older. It is estimated that up to 10 million Americans suffer from nasal polyps and the symptoms that accompany them.

View full press release here

Download full press release here